Compare DoorDash Inc (DASH) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Moderna, Inc. — how do they compare? DoorDash Inc trades at $191.73 (market cap $83.07B), while Moderna, Inc. trades at $205.17 (market cap $78.65B). The key difference: DoorDash Inc and Moderna, Inc. are close in size by market cap, and Moderna, Inc. is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Moderna, Inc. for 59 Days on average.
| DASH | MRNA | |
|---|---|---|
Market Cap | $83.07B | $78.65B |
Volume | 3,242,567 | 37,373,437 |
Sector | Media | Health |
52-Week High | $275.44 | $203.46 |
52-Week Low | $146.60 | $22.36 |
Typical Hold Time | 59 Days | 59 Days |
Enterprise Value | $81.03B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $13.72 billion in 2025, and achieved profitability with a net income margin of 6.81%. Recent developments include the launch of AI-powered text ordering and drone delivery expansion, signaling innovation in its core delivery business.
The outlook is positive with a consensus price target of $255.80, though high valuation multiples and mixed quarterly earnings misses pose risks. Investor sentiment is bolstered by analyst optimism, but regulatory scrutiny and competitive pressures remain key concerns for sustained growth.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
